ReviewSeminars in immunology2018
Targeting complement-mediated immunoregulation for cancer immunotherapy.
Review in Seminars in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 65 citations in OpenAlex.
- Systemic and local dysregulation of the complement system in glioma: a comprehensive systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Liposomes in tumor treatment: a double-edged sword.Science China. Life sciences · 2026Review
- ICIsAtlas reveals a suppressive NK cell niche in pan-cancer immunotherapy profiles.Communications biology · 2026Article
- The Complosome: An Emerging Intracellular Complement Network in Cancer Development and Therapy.International journal of molecular sciences · 2026Review
- Inherited genetic risk factors in young-onset lung cancer.medRxiv : the preprint server for health sciences · 2026Article
- In vivo CAR engineering for immunotherapy.Nature reviews. Immunology · 2025Review
- MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity.Discover oncology · 2025Article
- Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.Journal of neurology · 2025Article
- Complement activation at the interface between adipocytes and cancer cells drives tumor progression.JCI insight · 2025Article
- Advances in immunological sorting of X and Y chromosome-bearing sperm: from proteome to sex-specific proteins.Frontiers in veterinary science · 2025Review
- Complement Factor H Promotes the Growth of Lung Adenocarcinoma Cells through the JAK2/STAT3 Signaling Pathway.Current cancer drug targets · 2025Article
- Exploring the Role of Cellular Interactions in the Colorectal Cancer Microenvironment.Journal of immunology research · 2025Review
- Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer.World journal of gastrointestinal oncology · 2024Review
- C5aR plus MEK inhibition durably targets the tumor milieu and reveals tumor cell phagocytosis.Life science alliance · 2024Article
- Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.Cancer immunology, immunotherapy : CII · 2023Article
- Immunotherapy: A new target for cancer cure (Review).Oncology reports · 2023Review
- Prognostic Model and Tumor Immune Microenvironment Analysis of Complement-Related Genes in Gastric Cancer.Journal of inflammation research · 2023Article
- gC1qR: A New Target for Cancer Immunotherapy.Frontiers in immunology · 2023Review
- Characterization of osteosarcoma subtypes mediated by macrophage-related genes and creation and validation of a risk score system to quantitatively assess the prognosis of osteosarcoma and reflect the tumor microenvironment.Annals of translational medicine · 2022Article
- Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Complement was initially discovered as an assembly of plasma proteins "complementing" the cytolytic activity of antibodies. However, our current knowledge places this complex system of several plasma proteins, receptors, and regulators in the center of innate immunity as a bridge between the initial innate responses and adaptive immune reactions. Consequently, complement appears to be pivotal for elimination of pathogens, not only as an early response defense, but by directing the subsequent adaptive immune response. The discovery of functional intracellular complement and its roles in cellular metabolism opened novel avenues for research and potential therapeutic implications. The recent studies demonstrating immunoregulatory functions of complement in the tumor microenvironment and the premetastatic niche shifted the paradigm on our understanding of functions of the complement system in regulating immunity. Several complement proteins, through their interaction with cells in the tumor microenvironment and in metastasis-targeted organs, contribute to modulating tumor growth, antitumor immunity, angiogenesis, and therefore, the overall progression of malignancy and, perhaps, responsiveness of cancer to different therapies. Here, we focus on recent progress in our understanding of immunostimulatory vs. immunoregulatory functions of complement and potential applications of these findings to the design of novel therapies for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.